{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:43:37Z","timestamp":1770270217456,"version":"3.49.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T00:00:00Z","timestamp":1455840000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s00277-016-2617-y","type":"journal-article","created":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T00:31:23Z","timestamp":1455841883000},"page":"681-693","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives"],"prefix":"10.1007","volume":"95","author":[{"given":"Michele","family":"Malagola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Papayannidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,19]]},"reference":[{"key":"2617_CR1","doi-asserted-by":"crossref","unstructured":"Ottmann OG and Pfeifer H (2009) Management of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology, ASH Educational Book 371\u2013381","DOI":"10.1182\/asheducation-2009.1.371"},{"issue":"2","key":"2617_CR2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF01715353","volume":"64","author":"G G\u00f6tz","year":"1992","unstructured":"G\u00f6tz G, Weh HJ, Walter TA et al (1992) Clinical and prognostic significance of the Philadelphia chromosome in adult patients with acute lymphoblastic leukemia. Ann Hematol 64(2):97\u2013100","journal-title":"Ann Hematol"},{"issue":"8","key":"2617_CR3","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","volume":"85","author":"RA Larson","year":"1995","unstructured":"Larson RA, Dodge RK, Burns CP et al (1995) A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 85(8):2025\u201337","journal-title":"Blood"},{"key":"2617_CR4","doi-asserted-by":"crossref","unstructured":"Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A Collaborative Study of the Group Fran\u00e7ais de Cytog\u00e9n\u00e9tique H\u00e9matologique (1996) Blood 87(8):3135\u201342","DOI":"10.1182\/blood.V87.8.3135.bloodjournal8783135"},{"issue":"11","key":"2617_CR5","first-page":"3983","volume":"93","author":"M Wetzler","year":"1999","unstructured":"Wetzler M, Dodge RK, Mr\u00f3zek K et al (1999) Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood 93(11):3983\u201393","journal-title":"Blood"},{"issue":"12","key":"2617_CR6","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/sj.leu.2402289","volume":"15","author":"X Thomas","year":"2001","unstructured":"Thomas X, Dana\u00efla C, Le QH et al (2001) Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period. Leukemia 15(12):1811\u201322","journal-title":"Leukemia"},{"issue":"5","key":"2617_CR7","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/blood.V99.5.1536","volume":"99","author":"B Gleissner","year":"2002","unstructured":"Gleissner B, G\u00f6kbuget N, Bartram CR et al (2002) Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 99(5):1536\u201343","journal-title":"Blood"},{"issue":"3","key":"2617_CR8","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V99.3.863","volume":"99","author":"L Annino","year":"2002","unstructured":"Annino L, Vegna ML, Camera A et al (2002) Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 99(3):863\u201371","journal-title":"Blood"},{"issue":"7","key":"2617_CR9","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/sj.leu.2402526","volume":"16","author":"J Takeuchi","year":"2002","unstructured":"Takeuchi J, Kyo T, Naito K et al (2002) Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 16(7):1259\u201366","journal-title":"Leukemia"},{"issue":"12","key":"2617_CR10","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","volume":"101","author":"H Kantarjian","year":"2004","unstructured":"Kantarjian H, Thomas D, O\u2019Brien S et al (2004) Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 101(12):2788\u2013801","journal-title":"Cancer"},{"issue":"8","key":"2617_CR11","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","volume":"109","author":"AV Moorman","year":"2007","unstructured":"Moorman AV, Harrison CJ, Buck GA et al (2007) Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 109(8):3189\u201397","journal-title":"Blood"},{"issue":"5","key":"2617_CR12","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2007-10-116186","volume":"111","author":"V Pullarkat","year":"2008","unstructured":"Pullarkat V, Slovak ML, Kopecky KJ et al (2008) Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood 111(5):2563\u201372","journal-title":"Blood"},{"issue":"4","key":"2617_CR13","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2141.2012.09095.x","volume":"157","author":"JI Sive","year":"2012","unstructured":"Sive JI, Buck G, Fielding A et al (2012) Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII\/ECOG2993 trial. Br J Haematol 157(4):463\u201371","journal-title":"Br J Haematol"},{"issue":"2","key":"2617_CR14","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood.V70.2.587.587","volume":"70","author":"SJ Forman","year":"1987","unstructured":"Forman SJ, O\u2019Donnell MR, Nademanee AP et al (1987) Bone marrow transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 70(2):587\u20138","journal-title":"Blood"},{"issue":"11","key":"2617_CR15","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1182\/blood.V79.11.3067.3067","volume":"79","author":"AJ Barrett","year":"1992","unstructured":"Barrett AJ, Horowitz MM, Ash RC et al (1992) Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 79(11):3067\u201370","journal-title":"Blood"},{"issue":"11","key":"2617_CR16","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1182\/blood.V85.11.3353.bloodjournal85113353","volume":"85","author":"NJ Chao","year":"1995","unstructured":"Chao NJ, Blume KG, Forman SJ et al (1995) Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 85(11):3353\u20134","journal-title":"Blood"},{"issue":"12","key":"2617_CR17","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1038\/sj.leu.2401589","volume":"13","author":"DS Snyder","year":"1999","unstructured":"Snyder DS, Nademanee AP, O\u2019Donnell MR et al (1999) Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. Leukemia 13(12):2053\u20138","journal-title":"Leukemia"},{"issue":"6","key":"2617_CR18","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1182\/blood.V97.6.1572","volume":"97","author":"JJ Cornelissen","year":"2001","unstructured":"Cornelissen JJ, Carston M, Kollman C et al (2001) Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 97(6):1572\u20137","journal-title":"Blood"},{"issue":"7","key":"2617_CR19","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2002-03-0704","volume":"100","author":"H Dombret","year":"2002","unstructured":"Dombret H, Gabert J, Boiron JM et al (2002) Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia\u2014results of the prospective multicenter LALA-94 trial. Blood 100(7):2357\u201366","journal-title":"Blood"},{"issue":"10","key":"2617_CR20","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/sj.bmt.1703951","volume":"31","author":"H Esp\u00e9rou","year":"2003","unstructured":"Esp\u00e9rou H, Boiron JM, Cayuela JM et al (2003) A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society. Bone Marrow Transplant 31(10):909\u201318","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2617_CR21","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.bmt.1705148","volume":"36","author":"M Yanada","year":"2005","unstructured":"Yanada M, Naoe T, Iida H et al (2005) Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease. Bone Marrow Transplant 36(10):867\u201372","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2617_CR22","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1182\/blood-2008-03-143115","volume":"112","author":"GG Laport","year":"2008","unstructured":"Laport GG, Alvarnas JC, Palmer JM et al (2008) Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood 112(3):903\u20139","journal-title":"Blood"},{"issue":"19","key":"2617_CR23","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1182\/blood-2009-01-199380","volume":"113","author":"AK Fielding","year":"2009","unstructured":"Fielding AK, Rowe JM, Richards SM et al (2009) Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII\/ECOG2993. Blood 113(19):4489\u201396","journal-title":"Blood"},{"key":"2617_CR24","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Sawyers CL, Kantarjian H et al (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038\u20131042","journal-title":"N Engl J Med"},{"key":"2617_CR25","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","volume":"100","author":"OG Ottmann","year":"2002","unstructured":"Ottmann OG, Druker BJ, Sawyers CL et al (2002) A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100:1965\u20131971","journal-title":"Blood"},{"key":"2617_CR26","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2141.2009.07666.x","volume":"145","author":"F Gruber","year":"2009","unstructured":"Gruber F, Mustjoki S, Porkka K (2009) Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia. Br J Haematol 145:581\u2013597","journal-title":"Br J Haematol"},{"key":"2617_CR27","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, O\u2019Brien S, Konopleva M, Kantarjian H (2015) New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer. doi: 10.1002\/cncr.29383","journal-title":"Cancer"},{"key":"2617_CR28","doi-asserted-by":"crossref","unstructured":"Fielding AK (2015) Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: a broader range of options, improved outcomes, and more therapeutic dilemmas. ASCO Educational Book, e352-359","DOI":"10.14694\/EdBook_AM.2015.35.e352"},{"key":"2617_CR29","doi-asserted-by":"crossref","unstructured":"Papayannidis C, Fazi P, Piciocchi A, et al. (2012) Treating Ph+ acute lymphoblastic leukemia (ALL) in the elderly: the sequence of two tyrosine kinase inhibitors (TKI) (nilotinib and imatinib) does not prevent mutations and relapse. Proc Annual Meeting ASH, Blood 120:21, Abstract 2601","DOI":"10.1182\/blood.V120.21.2601.2601"},{"key":"2617_CR30","unstructured":"Sartor C, Papayannidis C, Piciocchi A, et al. (2015) Sequential use of first and second generation TKIs are effective on prolonged overall survival in elderly population affected by Ph+ acute lymphoblastic leukemia: the GIMEMA experience. Proc Annual AACR Meeting, Abstract 5491"},{"key":"2617_CR31","doi-asserted-by":"crossref","unstructured":"Thomas DA, Faderl S, Cortes J, et al. (2004). Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103:4396\u20134407.","DOI":"10.1182\/blood-2003-08-2958"},{"key":"2617_CR32","unstructured":"Thomas DA, Kantarjian HM, Cortes JE, et al. (2008) Out- come after frontline therapy with the hyper-CVAD and imatinib mesylate regimen for adults with de novo or minimally treated Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL). Proc ASCO Annual Meeting 26, Abstract 7019"},{"key":"2617_CR33","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/sj.leu.2403886","volume":"19","author":"KH Lee","year":"2005","unstructured":"Lee KH, Lee JH, Choi SJ et al (2005) Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 19:1509\u20131516","journal-title":"Leukemia"},{"key":"2617_CR34","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","volume":"24","author":"M Yanada","year":"2006","unstructured":"Yanada M, Takeuchi J, Sugiura I et al (2006) High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 24:460\u2013466","journal-title":"J Clin Oncol"},{"key":"2617_CR35","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3324\/haematol.11891","volume":"93","author":"M Yanada","year":"2008","unstructured":"Yanada M, Takeuchi J, Sugiura I et al (2008) Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Haematologica 93:287\u2013290","journal-title":"Haematologica"},{"key":"2617_CR36","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2005-11-4386","volume":"108","author":"B Wassmann","year":"2006","unstructured":"Wassmann B, Pfeifer H, Goekbuget N et al (2006) Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph\u2009+\u2009ALL). Blood 108:1469\u20131477","journal-title":"Blood"},{"key":"2617_CR37","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/sj.leu.2404320","volume":"20","author":"A Delannoy","year":"2006","unstructured":"Delannoy A, Delabesse E, Lheritier V et al (2006) Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia 20:1526\u20131532","journal-title":"Leukemia"},{"key":"2617_CR38","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2006-03-011908","volume":"109","author":"A Labarthe de","year":"2007","unstructured":"de Labarthe A, Rousselot P, Huguet-Rigal F et al (2007) Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 109:1408\u20131413","journal-title":"Blood"},{"key":"2617_CR39","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1200\/JCO.2010.28.1287","volume":"28","author":"R Bassan","year":"2010","unstructured":"Bassan R, Rossi G, Pogliani EM et al (2010) Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group Protocol 09\/00. J Clin Oncol 28:3644\u20133652","journal-title":"J Clin Oncol"},{"issue":"6","key":"2617_CR40","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2013-09-529008","volume":"123","author":"AK Fielding","year":"2014","unstructured":"Fielding AK, Foroni L, Gerrard G et al (2014) UKALLXII\/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood 123(6):843\u201350","journal-title":"Blood"},{"issue":"24","key":"2617_CR41","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","volume":"125","author":"Y Chalandon","year":"2015","unstructured":"Chalandon Y, Thomas X, Hayette S et al (2015) Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood 125(24):3711\u20133719","journal-title":"Blood"},{"key":"2617_CR42","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/cncr.22631","volume":"109","author":"OG Ottmann","year":"2007","unstructured":"Ottmann OG, Wassmann B, Pfeifer H et al (2007) Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromo-some-positive acute lymphoblastic leukemia (Ph\u2009+\u2009ALL). Cancer 109:2068\u20132076","journal-title":"Cancer"},{"key":"2617_CR43","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2006-10-052746","volume":"109","author":"M Vignetti","year":"2007","unstructured":"Vignetti M, Fazi P, Cimino G et al (2007) Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive acute lymphoblastic leukemia patients without additional chemotherapy: results of the GIMEMA LAL0201-B protocol. Blood 109:3676\u20133678","journal-title":"Blood"},{"key":"2617_CR44","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H et al (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354:2531\u20132541","journal-title":"N Engl J Med"},{"issue":"11","key":"2617_CR45","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O\u2019Hare","year":"2005","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP et al (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65(11):4500\u20134505","journal-title":"Cancer Res"},{"issue":"23","key":"2617_CR46","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.1158\/1078-0432.CCR-06-1112","volume":"12","author":"FR Luo","year":"2006","unstructured":"Luo FR, Yang Z, Camuso A et al (2006) Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res 12(23):7180\u20137186","journal-title":"Clin Cancer Res"},{"key":"2617_CR47","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood-2007-02-073528","volume":"110","author":"O Ottmann","year":"2007","unstructured":"Ottmann O, Dombret H, Martinelli G et al (2007) Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a Phase II study. Blood 110:2309\u20132315","journal-title":"Blood"},{"key":"2617_CR48","unstructured":"Porkka K, Martinelli G, Ottman OG, et al. (2008) Dasatinib efficacy in patients with imatinib-resistant\/-intolerant Philadelphia-chromosome-positive acute lymphoblastic leukemia: 24-month data from START-L. Proc SIES Annual Meeting, Haematologica 93(s1):1, Abstract 0001"},{"issue":"12","key":"2617_CR49","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood-2009-12-261586","volume":"116","author":"F Ravandi","year":"2010","unstructured":"Ravandi F, O\u2019Brien S, Thomas D et al (2010) First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 116(12):2070\u20137","journal-title":"Blood"},{"key":"2617_CR50","author":"F Ravandi","year":"2015","unstructured":"Ravandi F, O\u2019Brien SM, Cortes JE et al (2015) Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. doi: 10.1002\/cncr.29646","journal-title":"Cancer"},{"key":"2617_CR51","doi-asserted-by":"crossref","unstructured":"Rousselot P, Hayette S, Re \u0301cher C, et al. (2010) Dasatinib (Sprycel) and low intensity chemotherapy for f\u0131rst-line treatment in elderly patients with de novo Philadelphia positive ALL (EWALL-PH-01): kinetic of response, resistance and prognostic significance. Proc Annual AS Meeting Blood 116:21, Abstract 1204","DOI":"10.1182\/blood.V116.21.172.172"},{"issue":"25","key":"2617_CR52","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","volume":"118","author":"R Foa","year":"2011","unstructured":"Foa R, Vitale A, Vignetti M et al (2011) Dasatinib as first-line treatment for adult patients with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia. Blood 118(25):6521\u20138","journal-title":"Blood"},{"key":"2617_CR53","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W et al (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7:129\u2013141","journal-title":"Cancer Cell"},{"key":"2617_CR54","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/cncr.21299","volume":"104","author":"S Verstovsek","year":"2005","unstructured":"Verstovsek S, Golemovic M, Kantarjian H et al (2005) AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer 104:1230\u20131236","journal-title":"Cancer"},{"key":"2617_CR55","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1476-4598-6-67","volume":"6","author":"P Kaur","year":"2007","unstructured":"Kaur P, Feldhahn N, Zhang B et al (2007) Nilotinib treatment in mouse models of P190 Bcr\/Abl lymphoblastic leukemia. Mol Cancer 6:67\u201375","journal-title":"Mol Cancer"},{"issue":"5","key":"2617_CR56","first-page":"765","volume":"39","author":"RP La","year":"2009","unstructured":"La RP, Holm-Eriksen S, Konig H et al (2009) Phopsho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib. Haematologica 39(5):765\u2013769","journal-title":"Haematologica"},{"issue":"6","key":"2617_CR57","volume":"9","author":"H Zhang","year":"2014","unstructured":"Zhang H, Gu L, Liu T et al (2014) Inhibition of MDM2 by nilotinib contributes to cytotoxicity in both Philadelphia-positive and negative acute lymphoblastic leukemia. PLoS ONE 9(6), e100960","journal-title":"PLoS ONE"},{"key":"2617_CR58","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.leukres.2008.03.031","volume":"33","author":"M Tiribelli","year":"2009","unstructured":"Tiribelli M, Sperotto A, Candoni A et al (2009) Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia relapsing after allogeneic stem cell transplantation and resistant to imatinib. Leuk Res 33:174\u2013177","journal-title":"Leuk Res"},{"key":"2617_CR59","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.leukres.2012.04.019","volume":"36","author":"PKT Liu","year":"2012","unstructured":"Liu PKT, Huang Q, Ye Y et al (2012) A novel I293MP mutation within BCR-ABL kinase domain in a Ph-positive acute lymphoblastic leukemia patients presenting resistant to imatinib but sensitive to nilotinib. Leuk Res 36:159\u2013162","journal-title":"Leuk Res"},{"key":"2617_CR60","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/bmt.2009.6","volume":"44","author":"S Merante","year":"2009","unstructured":"Merante S, Colombo AA, Calatroni S et al (2009) Nilotinib restores long-term full-donor chimerism in Ph-positive acute lymphoblastic leukemia relapsed after allogeneic transplantation. Bone Marrow Transpl 44:263\u2013264","journal-title":"Bone Marrow Transpl"},{"key":"2617_CR61","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s12185-009-0327-0","volume":"89","author":"A Tojo","year":"2009","unstructured":"Tojo A, Usuki K, Urabe A et al (2009) A phase I\/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed\/refratory Ph+ ALL. Int J Hematol 89:679\u2013688","journal-title":"Int J Hematol"},{"key":"2617_CR62","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/leu.2012.324","volume":"27","author":"OG Ottmann","year":"2013","unstructured":"Ottmann OG, Larson RA, Kantrajian HM et al (2013) Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 27:1411\u20131413","journal-title":"Leukemia"},{"key":"2617_CR63","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L et al (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354:2542\u20132541","journal-title":"N Engl J Med"},{"issue":"6","key":"2617_CR64","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2015-03-636548","volume":"126","author":"DY Kim","year":"2015","unstructured":"Kim DY, Joo YD, Lim SN et al (2015) Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood 126(6):746\u201356","journal-title":"Blood"},{"issue":"8","key":"2617_CR65","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1182\/blood-2004-05-1851","volume":"104","author":"T O\u2019Hare","year":"2004","unstructured":"O\u2019Hare T, Pollock R, Stoffrege EP et al (2004) Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor; implications for CML. Blood 104(8):2532\u20132539","journal-title":"Blood"},{"key":"2617_CR66","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"6","author":"T O\u2019Hare","year":"2009","unstructured":"O\u2019Hare T, Shakespeare WC, Zhu X et al (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 6:401\u201312","journal-title":"Cancer Cell"},{"key":"2617_CR67","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1038\/leu.2015.35","volume":"29","author":"L Lu","year":"2015","unstructured":"Lu L, Saunders VA, Leclercq TM et al (2015) Ponatinib is not transported by ABCB1, ABCG2 or OCT1 in CML cells. Leukemia 29:1792\u20131794","journal-title":"Leukemia"},{"key":"2617_CR68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccr.2014.07.006","volume":"26","author":"MS Zabriskie","year":"2014","unstructured":"Zabriskie MS, Eide CA, Tantravahi SK et al (2014) BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell 26:1\u201315","journal-title":"Cancer Cell"},{"key":"2617_CR69","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","volume":"367","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kantarjian H, Shah NP et al (2012) Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 367:2075\u20132088","journal-title":"N Engl J Med"},{"issue":"19","key":"2617_CR70","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J et al (2013) A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369(19):1783\u201396","journal-title":"N Engl J Med"},{"key":"2617_CR71","doi-asserted-by":"crossref","unstructured":"Khoury HJ, Cortes IE, Kim D-W, et al. Analysis of the cardiovascular risk profile of Ph+ leukemia patients treated with ponatinib. ASCO 2013, Abstract 7048","DOI":"10.1200\/jco.2013.31.15_suppl.7048"},{"key":"2617_CR72","first-page":"1111","volume":"6","author":"K Price","year":"2013","unstructured":"Price K, Saleem N, Lee G et al (2013) Potential fo ponatininb to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Oncol Targets Ther 6:1111\u201318","journal-title":"Oncol Targets Ther"},{"issue":"15","key":"2617_CR73","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","volume":"16","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, Kantarjian H, Ravandi F et al (2015) Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-centre, phase 2 study. Lancet Oncol 16(15):1547\u201355","journal-title":"Lancet Oncol"},{"key":"2617_CR74","unstructured":"Martinelli G., GIMEMA AL WP (2015) Personal communication"},{"key":"2617_CR75","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12967-015-0453-9","volume":"13","author":"A Sadarangani","year":"2015","unstructured":"Sadarangani A, Pined G, Lennon KM et al (2015) GLI2 inhibition abrogates human leukemia stem cell dormancy. J Transl Med 13:98","journal-title":"J Transl Med"},{"key":"2617_CR76","doi-asserted-by":"crossref","unstructured":"Wylie A, Schoepfer J, Berellini G, et al. (2014) ABL001, a potent allosteric inhibitor of BCR-ABL, prevents emergence of resistant disease when administered in combination with nilotinib in an in vivo murine model of chronic myeloid leukemia. Annual Meeting ASH, Blood 124:21, Abstract 398","DOI":"10.1182\/blood.V124.21.398.398"},{"key":"2617_CR77","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1182\/blood-2004-09-3785","volume":"105","author":"S Lee","year":"2005","unstructured":"Lee S, Kim YJ, Min CK et al (2005) The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 105:3449\u201357","journal-title":"Blood"},{"issue":"15","key":"2617_CR78","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1182\/blood-2013-11-538728","volume":"123","author":"S Mizuta","year":"2014","unstructured":"Mizuta S, Matsuo K, Nishiwaki S et al (2014) Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL-positive acute lymphoblastic leukemia. Blood 123(15):2352\u201332","journal-title":"Blood"},{"key":"2617_CR79","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1182\/blood.V89.7.2602","volume":"89","author":"J Radich","year":"1997","unstructured":"Radich J, Gehly G, Lee A et al (1997) Detection of BCR-ABL transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 89:2602\u20139","journal-title":"Blood"},{"key":"2617_CR80","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2006-04-019836","volume":"109","author":"PA Carpenter","year":"2007","unstructured":"Carpenter PA, Snyder DS, Flowers ME et al (2007) Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 109:2791\u201393","journal-title":"Blood"},{"key":"2617_CR81","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/blood-2004-05-1746","volume":"106","author":"B Wassmann","year":"2005","unstructured":"Wassmann B, Pfeifer H, Stadler M et al (2005) Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 106:458\u201363","journal-title":"Blood"},{"key":"2617_CR82","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/bmt.2008.296","volume":"43","author":"MJ Burke","year":"2009","unstructured":"Burke MJ, Trotz B, Luo X et al (2009) Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival. Bone Marrow Transplant 43:107\u201313","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2617_CR83","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872\u2013884","journal-title":"Blood"},{"issue":"5","key":"2617_CR84","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.hoc.2009.07.007","volume":"23","author":"F Ravandi","year":"2009","unstructured":"Ravandi F, Kebriaei P (2009) Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematol Oncol Clin North Am 23(5):1043\u201363","journal-title":"Hematol Oncol Clin North Am"},{"issue":"9","key":"2617_CR85","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/ajh.24034","volume":"90","author":"C Gambacorti-Passerini","year":"2015","unstructured":"Gambacorti-Passerini C, Kantarjian H, Kim D et al (2015) Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance\/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol 90(9):755\u201368","journal-title":"Am J Hematol"},{"issue":"26","key":"2617_CR86","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2014-08-596403","volume":"125","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, O\u2019Brien S, Ravandi F, Kantarjian H (2015) Monoclonal antibodies in acute lymphoblastic leukemia. Blood 125(26):4010\u20134016","journal-title":"Blood"},{"issue":"26","key":"2617_CR87","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","volume":"125","author":"SL Maude","year":"2015","unstructured":"Maude SL, Teachey DT, Porter DL, Grupp SA (2015) CD-19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 125(26):4017\u20134023","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2617-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-016-2617-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2617-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T19:03:39Z","timestamp":1600196619000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-016-2617-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,19]]},"references-count":87,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["2617"],"URL":"https:\/\/doi.org\/10.1007\/s00277-016-2617-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,19]]}}}